GLP-1 drugs could reduce long-term sick leave: Study
Researchers found GLP-1 users took 17% less long-term sick leave, with average savings of about $866 per worker.
- A new National Bureau of Economic Research study published this month found patients using GLP-1 medications like Ozempic and Wegovy took 17% less long-term sick leave, according to research examining data from Denmark.
- Reducing long-term absences translates into financial savings of up to 1.5% of an individual's salary, or roughly $866 on average, as Denmark's employers cover short-term leave while the government funds absences exceeding 30 days.
- Jonathan Zhang, a professor at Duke University, explained that health improvements associated with GLP-1 drugs help explain why workers miss fewer days by treating diabetes and obesity while reducing cardiovascular risks.
10 Articles
10 Articles
GLP-1 Drugs Could Reduce Long-Term Sick Leave
GLP-1 drugs, known for weight loss, may reduce long-term sick leave by 17%, saving up to 1.5% of salaries, according to a study. Originally for diabetes, these drugs are gaining popularity for broader health benefits, including reduced risks of cardiovascular disease and some cancers.
Ozempic And Wegovy May Boost Workplace Productivity: New Study Links GLP-1 Drugs to a 17% Drop in Sick Days
A new economic study suggests that GLP-1 medications like Ozempic or Mounjaro could reduce employee sick leave, potentially saving money for both businesses and governments while improving workplace
DATA: GLP-1 Medications Reduce Employee Sick Days by 17%.
A new study has highlighted the apparent economic benefits of GLP-1 medications like Ozempic and Wegovy, such as reducing long-term absences, saving money for employers and governments, and boosting productivity.PULSE POINTS WHAT HAPPENED: A new study has revealed that GLP-1 weight-loss drugs reduced long-term sick leave by almost 20 percent. DETAIL: According to a new study by the National Bureau of Economic Research, GLP-1 drugs reduced long-t…
Coverage Details
Bias Distribution
- 45% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
